Literature DB >> 11568013

GATA1-Cre mediates Piga gene inactivation in the erythroid/megakaryocytic lineage and leads to circulating red cells with a partial deficiency in glycosyl phosphatidylinositol-linked proteins (paroxysmal nocturnal hemoglobinuria type II cells).

M Jasinski1, P Keller, Y Fujiwara, S H Orkin, M Bessler.   

Abstract

Patients with paroxysmal nocturnal hemoglobinuria (PNH) have blood cells deficient in glycosyl phosphatidylinositol (GPI)-linked proteins owing to a somatic mutation in the X-linked PIGA gene. To target Piga recombination to the erythroid/megakaryocytic lineage in mice, the Cre/loxP system was used, and Cre was expressed under the transcriptional regulatory sequences of GATA-1. Breeding of GATA1-cre (G) transgenic mice with mice carrying a floxed Piga (L) allele was associated with high embryonic lethality. However, double-transgenic (GL) mice that escaped early recombination looked healthy and were observed for 16 months. Flow cytometric analysis of peripheral blood cells showed that GL mice had up to 100% of red cells deficient in GPI-linked proteins. The loss of GPI-linked proteins on the cell surface occurred late in erythroid differentiation, causing a proportion of red cells to express low residual levels of GPI-linked proteins. Red cells with residual expression of GPI-linked proteins showed an intermediate sensitivity toward complement and thus resemble PNH type II cells in patients with PNH. Recombination of the floxed Piga allele was also detected in cultured megakaryocytes, mast cells, and eosinophils, but not in neutrophils, lymphocytes, or nonhematopoietic tissues. In summary, GATA1-Cre causes high-efficiency Piga gene inactivation in a GATA-1-specific pattern. For the first time, mice were generated that have almost 100% of red cells deficient in GPI-linked proteins. These animals will be valuable to further investigate the consequences of GPI-anchor deficiency on erythroid/megakaryocytic cells.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11568013     DOI: 10.1182/blood.v98.7.2248

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  20 in total

1.  Transcriptional silencing of {gamma}-globin by BCL11A involves long-range interactions and cooperation with SOX6.

Authors:  Jian Xu; Vijay G Sankaran; Min Ni; Tobias F Menne; Rishi V Puram; Woojin Kim; Stuart H Orkin
Journal:  Genes Dev       Date:  2010-04-15       Impact factor: 11.361

2.  Comparative analysis of the efficiency and specificity of myeloid-Cre deleting strains using ROSA-EYFP reporter mice.

Authors:  Clare L Abram; Gray L Roberge; Yongmei Hu; Clifford A Lowell
Journal:  J Immunol Methods       Date:  2014-05-22       Impact factor: 2.303

3.  Paroxysmal nocturnal hemoglobinuria: pathophysiology, natural history and treatment options in the era of biological agents.

Authors:  Antonio M Risitano; Bruno Rotoli
Journal:  Biologics       Date:  2008-06

4.  A novel interaction between FlnA and Syk regulates platelet ITAM-mediated receptor signaling and function.

Authors:  Hervé Falet; Alice Y Pollitt; Antonija Jurak Begonja; Sarah E Weber; Daniel Duerschmied; Denisa D Wagner; Steve P Watson; John H Hartwig
Journal:  J Exp Med       Date:  2010-08-16       Impact factor: 14.307

5.  Overexpression of survivin initiates hematologic malignancies in vivo.

Authors:  S Small; G Keerthivasan; Z Huang; S Gurbuxani; J D Crispino
Journal:  Leukemia       Date:  2010-09-30       Impact factor: 11.528

6.  Bcl11a Deficiency Leads to Hematopoietic Stem Cell Defects with an Aging-like Phenotype.

Authors:  Sidinh Luc; Jialiang Huang; Jennifer L McEldoon; Ece Somuncular; Dan Li; Claire Rhodes; Shahan Mamoor; Serena Hou; Jian Xu; Stuart H Orkin
Journal:  Cell Rep       Date:  2016-09-20       Impact factor: 9.423

7.  Progression through key stages of haemopoiesis is dependent on distinct threshold levels of c-Myb.

Authors:  Nikla Emambokus; Alexandros Vegiopoulos; Ben Harman; Eric Jenkinson; Graham Anderson; Jon Frampton
Journal:  EMBO J       Date:  2003-09-01       Impact factor: 11.598

8.  Developmental and species-divergent globin switching are driven by BCL11A.

Authors:  Vijay G Sankaran; Jian Xu; Tobias Ragoczy; Gregory C Ippolito; Carl R Walkley; Shanna D Maika; Yuko Fujiwara; Masafumi Ito; Mark Groudine; M A Bender; Philip W Tucker; Stuart H Orkin
Journal:  Nature       Date:  2009-08-05       Impact factor: 49.962

Review 9.  Complement in paroxysmal nocturnal hemoglobinuria: exploiting our current knowledge to improve the treatment landscape.

Authors:  Dimitrios C Mastellos; Daniel Ricklin; Despina Yancopoulou; Antonio Risitano; John D Lambris
Journal:  Expert Rev Hematol       Date:  2014-09-02       Impact factor: 2.929

10.  The pathophysiology of paroxysmal nocturnal hemoglobinuria and treatment with eculizumab.

Authors:  Richard Kelly; Stephen Richards; Peter Hillmen; Anita Hill
Journal:  Ther Clin Risk Manag       Date:  2009       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.